Rigel Pharmaceuticals, Inc. (RIGL)

Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS SOUTH SAN FRANCISCO, Calif. , Oct. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the first patient has been enrolled in the dose expansion phase of the ongoing Phase 1b study of R2891 in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS).

SOUTH SAN FRANCISCO, Calif. , Oct. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

Rigel's Tavalisse drives strong sales, but expansion with Rezlidhia, Gavreto, and pipeline candidates could shape its long-term growth story.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Rigel (RIGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Rigel Pharmaceuticals is a commercial-stage biotech growing revenue with three marketed drugs and a promising pipeline. RIGL's product sales grew 72% YoY in 1H FY2025, with diversification reducing reliance on TAVALISSE and GAVRETO showing strong adoption. On FY2025 revenue projections, Rigel trades at ~2.8x forward EV/sales; valuing the company in line with the sector median implies a share price of approximately $63.

Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.

RIGL shares surge 77% in three months as Tavalisse drives record sales along with other products while boosting the company's 2025 outlook.

RIGL's top line keeps growing on strong sales momentum for lead product, Tavalisse, while other products support growth.

Does Rigel Pharmaceuticals (RIGL) have what it takes to be a top stock pick for momentum investors? Let's find out.

SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September: Citi's 2025 Biopharma Back to School Conference in Boston, MA Rigel will participate in one-on-one meetings on Tuesday, September 2.

Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Rigel Pharmaceuticals (RIGL) is up 88% in August and more than tripled its stock price over the last year. The staggering upside rally began with a massive earnings beat and raised guidance.

Rigel's Q2 results were outstanding, with revenue nearly doubling and net income surging, driven by strong commercial momentum for TAVALISSE, GAVRETO, and REZLIDHIA. Management raised 2025 guidance, expecting positive net income and robust sales growth, signaling Rigel's transition to a self-sustaining, growth-focused biotech. Pipeline progress, especially with R289 and REZLIDHIA label expansion, offers long-term catalysts, but investors must weigh risks from nonrecurring revenue and clinical execution.

Rigel Pharmaceuticals (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

RIGL, APG and CLSK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2025.